LB Pharmaceuticals Inc
LBRX
$47.78
$3.517.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -189.02% | 25.04% | 59.71% | -- | -- |
| Total Depreciation and Amortization | 42.86% | 94.91% | 254.40% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 884.12% | 82.63% | -11.35% | -- | -- |
| Change in Net Operating Assets | 54.13% | -216.69% | -534.89% | -- | -- |
| Cash from Operations | -92.98% | -0.05% | 31.26% | -- | -- |
| Capital Expenditure | 38.56% | 89.50% | 91.29% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -187.72% | -176.94% | -255.54% | -- | -- |
| Cash from Investing | -189.84% | -178.14% | -260.98% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,140,270.00% | 1,860,882.61% | 1,425,973.91% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -1,389.17% | -- | -- |
| Cash from Financing | 1,981,770.00% | 1,723,347.83% | 689.67% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,632.89% | 11,123.00% | 2,591.43% | -- | -- |